Abstract
Osteoporosis is a skeletal disorder characterized by bone loss, which results in architectural deterioration of the skeleton, compromised bone strength and an increased risk of fragility fractures. Most current therapies for osteoporosis stabilize the skeleton by inhibiting bone resorption (antiresorptive agents), but the development of anabolic therapies that can increase bone formation and bone mass is of great interest. Wnt signalling induces differentiation of bone-forming cells (osteoblasts) and suppresses the development of bone-resorbing cells (osteoclasts). The Wnt pathway is controlled by antagonists that interact either directly with Wnt proteins or with Wnt co-receptors. The importance of Wnt signalling in bone formation is indicated by skeletal disorders such as sclerosteosis and van Buchem syndrome, which are caused by mutations in the gene encoding the Wnt antagonist sclerostin (SOST). Experiments in mice have shown that downregulation or neutralization of Wnt antagonists enhances bone formation. Phase II clinical trials show that 1-year treatment with antisclerostin antibodies increases bone formation, decreases bone resorption and leads to a substantial increase in BMD. Consequently, Wnt signalling can be targeted by the neutralization of its extracellular antagonists to obtain a skeletal anabolic response.
Key Points
-
Wnt signalling has a critical role in skeletal development and adult skeletal homeostasis
-
Wnt signalling is regulated by a family of secreted Wnt antagonists
-
Canonical Wnt signalling enhances osteoblastogenesis and bone formation and decreases osteoclastogenesis and bone resorption
-
Mutations in the genes encoding Wnt co-receptors and Wnt antagonists cause profound changes in bone mass
-
Wnt antagonists can be targeted to enhance Wnt signalling in the skeleton
-
Treatment with humanized antisclerostin antibodies increases BMD in humans; clinical trials to assess the antifracture efficacy of this intervention are underway
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
NIH Consensus Development Panel on Osteoporosis Prevention Diagnosis and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA 285, 785–795 (2001).
Bone, H. Future directions in osteoporosis therapeutics. Endocrinol. Metab. Clin. North Am. 41, 655–661 (2012).
Diab, D. L. & Watts, N. B. Bisphosphonates in the treatment of osteoporosis. Endocrinol. Metab. Clin. North Am. 41, 487–506 (2012).
Bianco, P. & Gehron Robey, P. Marrow stromal stem cells. J. Clin. Invest. 105, 1663–1668 (2000).
Canalis, E. The fate of circulating osteoblasts. N. Engl. J. Med. 352, 2014–2016 (2005).
Canalis, E., Economides, A. N. & Gazzerro, E. Bone morphogenetic proteins, their antagonists, and the skeleton. Endocr. Rev. 24, 218–235 (2003).
Deregowski, V., Gazzerro, E., Priest, L., Rydziel, S. & Canalis, E. Notch 1 overexpression inhibits osteoblastogenesis by suppressing Wnt/β-catenin but not bone morphogenetic protein signaling. J. Biol. Chem. 281, 6203–6210 (2006).
Monroe, D. G., McGee-Lawrence, M. E., Oursler, M. J. & Westendorf, J. J. Update on Wnt signaling in bone cell biology and bone disease. Gene 492, 1–18 (2012).
Aarden, E. M., Burger, E. H. & Nijweide, P. J. Function of osteocytes in bone. J. Cell. Biochem. 55, 287–299 (1994).
Bonewald, L. F. The amazing osteocyte. J. Bone Miner. Res. 26, 229–238 (2011).
Tatsumi, S. et al. Targeted ablation of osteocytes induces osteoporosis with defective mechanotransduction. Cell Metab. 5, 464–475 (2007).
Canalis, E., Giustina, A. & Bilezikian, J. P. Mechanisms of anabolic therapies for osteoporosis. N. Engl. J. Med. 357, 905–916 (2007).
Parfitt, A. M. The bone remodeling compartment: a circulatory function for bone lining cells. J. Bone Miner. Res. 16, 1583–1585 (2001).
Seeman, E. & Delmas, P. D. Bone quality—the material and structural basis of bone strength and fragility. N. Engl. J. Med. 354, 2250–2261 (2006).
Parfitt, A. M. The mechanism of coupling: a role for the vasculature. Bone 26, 319–323 (2000).
Ozcivici, E. et al. Mechanical signals as anabolic agents in bone. Nat. Rev. Rheumatol. 6, 50–59 (2010).
Turner, C. H. & Pavalko, F. M. Mechanotransduction and functional response of the skeleton to physical stress: the mechanisms and mechanics of bone adaptation. J. Orthop. Sci. 3, 346–355 (1998).
Nakashima, T. et al. Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nat. Med. 17, 1231–1234 (2011).
Xiong, J. et al. Matrix-embedded cells control osteoclast formation. Nat. Med. 17, 1235–1241 (2011).
Xiong, J. & O'Brien, C. A. Osteocyte RANKL: new insights into the control of bone remodeling. J. Bone Miner. Res. 27, 499–505 (2012).
Honma, M. et al. RANKL subcellular trafficking and regulatory mechanisms in osteocytes. J. Bone Miner. Res. http://dx.doi.org/10.1002/jbmr.1941.
Clevers, H. Wnt/β-catenin signaling in development and disease. Cell 127, 469–480 (2006).
Kramer, I. et al. Osteocyte Wnt/β-catenin signaling is required for normal bone homeostasis. Mol. Cell Biol. 30, 3071–3085 (2010).
Robinson, J. A. et al. Wnt/β-catenin signaling is a normal physiological response to mechanical loading in bone. J. Biol. Chem. 281, 31720–31728 (2006).
Liu, C. et al. Control of β-catenin phosphorylation/degradation by a dual-kinase mechanism. Cell 108, 837–847 (2002).
Behrens, J. et al. Functional interaction of β-catenin with the transcription factor LEF-1. Nature 382, 638–642 (1996).
van de Wetering, M. et al. Armadillo coactivates transcription driven by the product of the Drosophila segment polarity gene dTCF. Cell 88, 789–799 (1997).
Liu, F., Kohlmeier, S. & Wang, C. Y. Wnt signaling and skeletal development. Cell Signal. 20, 999–1009 (2008).
Akiyama, H. et al. Interactions between Sox9 and β-catenin control chondrocyte differentiation. Genes Dev. 18, 1072–1087 (2004).
Glass, D. A. et al. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev. Cell 8, 751–764 (2005).
Holmen, S. L. et al. Essential role of β-catenin in postnatal bone acquisition. J. Biol. Chem. 280, 21162–21168 (2005).
Bennett, C. N. et al. Regulation of osteoblastogenesis and bone mass by Wnt10b. Proc. Natl Acad. Sci. USA 102, 3324–3329 (2005).
Boyden, L. M. et al. High bone density due to a mutation in LDL-receptor-related protein 5. N. Engl. J. Med. 346, 1513–1521 (2002).
Gong, Y. et al. LDL-receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 107, 513–523 (2001).
Krishnan, V., Bryant, H. U. & MacDougald, O. A. Regulation of bone mass by Wnt signaling. J. Clin. Invest. 116, 1202–1209 (2006).
Bennett, C. N. et al. Wnt10b increases postnatal bone formation by enhancing osteoblast differentiation. J. Bone Miner. Res. 22, 1924–1932 (2007).
Day, T. F., Guo, X., Garrett-Beal, L. & Yang, Y. Wnt/β-catenin signaling in mesenchymal progenitors controls osteoblast and chondrocyte differentiation during vertebrate skeletogenesis. Dev. Cell 8, 739–750 (2005).
Gaur, T. et al. Canonical WNT signaling promotes osteogenesis by directly stimulating Runx2 gene expression. J. Biol. Chem. 280, 33132–33140 (2005).
Nakashima, K. et al. The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation. Cell 108, 17–29 (2002).
Wei, W. et al. Biphasic and dosage-dependent regulation of osteoclastogenesis by β-catenin. Mol. Cell Biol. 31, 4706–4719 (2011).
Chen, J. & Long, F. β-catenin promotes bone formation and suppresses bone resorption in postnatal growing mice. J. Bone Miner. Res. 28, 1160–1169 (2013).
Otero, K. et al. TREM2 and β-catenin regulate bone homeostasis by controlling the rate of osteoclastogenesis. J. Immunol. 188, 2612–2621 (2012).
Playford, M. P., Bicknell, D., Bodmer, W. F. & Macaulay, V. M. Insulin-like growth factor 1 regulates the location, stability, and transcriptional activity of β-catenin. Proc. Natl Acad. Sci. USA 97, 12103–12108 (2000).
Gazzerro, E. & Canalis, E. Skeletal actions of insulin-like growth factors. Expert Rev. Endocrinol. Metab. 1, 47–56 (2006).
Zanotti, S. & Canalis, E. NEMO-like kinase inhibits osteoblastogenesis by suppressing bone morphogenetic protein and Wnt canonical signaling. J. Cell Biochem. 113, 449–456 (2012).
Kawano, Y. & Kypta, R. Secreted antagonists of the Wnt signalling pathway. J. Cell Sci. 116, 2627–2634 (2003).
Robling, A. G. et al. Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost/sclerostin. J. Biol. Chem. 283, 5866–5875 (2008).
Tu, X. et al. Sost downregulation and local Wnt signaling are required for the osteogenic response to mechanical loading. Bone 50, 209–217 (2012).
Mao, B. et al. Kremen proteins are Dickkopf receptors that regulate Wnt/β-catenin signalling. Nature 417, 664–667 (2002).
Piters, E., Boudin, E. & van Hul, W. Wnt signaling: a win for bone. Arch. Biochem. Biophys. 473, 112–116 (2008).
Hsieh, J. C. et al. A new secreted protein that binds to Wnt proteins and inhibits their activities. Nature 398, 431–436 (1999).
Surmann-Schmitt, C. et al. Wif-1 is expressed at cartilage–mesenchyme interfaces and impedes Wnt3a-mediated inhibition of chondrogenesis. J. Cell Sci. 122, 3627–3637 (2009).
Vaes, B. L. et al. Microarray analysis reveals expression regulation of Wnt antagonists in differentiating osteoblasts. Bone 36, 803–811 (2005).
Haydon, R. C. et al. Cytoplasmic and/or nuclear accumulation of the β-catenin protein is a frequent event in human osteosarcoma. Int. J. Cancer 102, 338–342 (2002).
Kansara, M. et al. Wnt inhibitory factor 1 is epigenetically silenced in human osteosarcoma, and targeted disruption accelerates osteosarcomagenesis in mice. J. Clin. Invest. 119, 837–851 (2009).
Bodine, P. V. et al. The Wnt antagonist secreted frizzled-related protein-1 is a negative regulator of trabecular bone formation in adult mice. Mol. Endocrinol. 18, 1222–1237 (2004).
Nakanishi, R. et al. Osteoblast-targeted expression of Sfrp4 in mice results in low bone mass. J. Bone Miner. Res. 23, 271–277 (2008).
Bouwmeester, T., Kim, S., Sasai, Y., Lu, B. & De Robertis, E. M. Cerberus is a head-inducing secreted factor expressed in the anterior endoderm of Spemann's organizer. Nature 382, 595–601 (1996).
Glinka, A., Wu, W., Onichtchouk, D., Blumenstock, C. & Niehrs, C. Head induction by simultaneous repression of Bmp and Wnt signalling in Xenopus. Nature 389, 517–519 (1997).
Piccolo, S. et al. The head inducer Cerberus is a multifunctional antagonist of Nodal, BMP and Wnt signals. Nature 397, 707–710 (1999).
Li, X. et al. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J. Biol. Chem. 280, 19883–19887 (2005).
van Bezooijen, R. L. et al. Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. J. Exp. Med. 199, 805–814 (2004).
van Lierop, A. H., Witteveen, J. E., Hamdy, N. A. & Papapoulos, S. E. Patients with primary hyperparathyroidism have lower circulating sclerostin levels than euparathyroid controls. Eur. J. Endocrinol. 163, 833–837 (2010).
Bellido, T., Saini, V. & Pajevic, P. D. Effects of PTH on osteocyte function. Bone 54, 250–257 (2013).
Sawakami, K. et al. The Wnt co-receptor LRP5 is essential for skeletal mechanotransduction but not for the anabolic bone response to parathyroid hormone treatment. J. Biol. Chem. 281, 23698–23711 (2006).
Li, X. et al. Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J. Bone Miner. Res. 23, 860–869 (2008).
Loots, G. G. et al. Genomic deletion of a long-range bone enhancer misregulates sclerostin in van Buchem disease. Genome Res. 15, 928–935 (2005).
Winkler, D. G. et al. Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J. 22, 6267–6276 (2003).
Jastrzebski, S. et al. Changes in bone sclerostin levels in mice after ovariectomy vary independently of changes in serum sclerostin levels. J. Bone Miner. Res. 28, 618–626 (2013).
Ardawi, M. S., Al-Kadi, H. A., Rouzi, A. A. & Qari, M. H. Determinants of serum sclerostin in healthy pre- and postmenopausal women. J. Bone Miner. Res. 26, 2812–2822 (2011).
Lapauw, B. et al. Serum sclerostin levels in men with idiopathic osteoporosis. Eur. J. Endocrinol. 168, 615–620 (2013).
Mirza, F. S., Padhi, I. D., Raisz, L. G. & Lorenzo, J. A. Serum sclerostin levels negatively correlate with parathyroid hormone levels and free estrogen index in postmenopausal women. J. Clin. Endocrinol. Metab. 95, 1991–1997 (2010).
Itasaki, N. et al. Wise, a context-dependent activator and inhibitor of Wnt signalling. Development 130, 4295–4305 (2003).
Laurikkala, J., Kassai, Y., Pakkasjarvi, L., Thesleff, I. & Itoh, N. Identification of a secreted BMP antagonist, ectodin, integrating BMP, FGF, and SHH signals from the tooth enamel knot. Dev. Biol. 264, 91–105 (2003).
Niehrs, C. Function and biological roles of the Dickkopf family of Wnt modulators. Oncogene 25, 7469–7481 (2006).
Pinzone, J. J. et al. The role of Dickkopf-1 in bone development, homeostasis, and disease. Blood 113, 517–525 (2009).
Glinka, A. et al. Dickkopf-1 is a member of a new family of secreted proteins and functions in head induction. Nature 391, 357–362 (1998).
Li, J. et al. Dkk1-mediated inhibition of Wnt signaling in bone results in osteopenia. Bone 39, 754–766 (2006).
Morvan, F. et al. Deletion of a single allele of the Dkk1 gene leads to an increase in bone formation and bone mass. J. Bone Miner. Res. 21, 934–945 (2006).
Glantschnig, H. et al. Generation and selection of novel fully human monoclonal antibodies that neutralize Dickkopf-1 (DKK1) inhibitory function in vitro and increase bone mass in vivo. J. Biol. Chem. 285, 40135–40147 (2010).
Li, X. et al. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J. Bone Miner. Res. 24, 578–588 (2009).
Balemans, W. et al. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum. Mol. Genet. 10, 537–543 (2001).
van Hul, W. et al. van Buchem disease (hyperostosis corticalis generalisata) maps to chromosome 17q12–q21. Am. J. Hum. Genet. 62, 391–399 (1998).
Brunkow, M. E. et al. Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am. J. Hum. Genet. 68, 577–589 (2001).
Bhadada, S. K. et al. Novel SOST gene mutation in a sclerosteosis patient and her parents. Bone 52, 707–710 (2013).
Piters, E. et al. First missense mutation in the SOST gene causing sclerosteosis by loss of sclerostin function. Hum. Mutat. 31, E1526–E1543 (2010).
Gardner, J. C. et al. Bone mineral density in sclerosteosis; affected individuals and gene carriers. J. Clin. Endocrinol. Metab. 90, 6392–6395 (2005).
Balemans, W. et al. Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease. J. Med. Genet. 39, 91–97 (2002).
Staehling-Hampton, K. et al. A 52-kb deletion in the SOST–MEOX1 intergenic region on 17q12–q21 is associated with van Buchem disease in the Dutch population. Am. J. Med. Genet. 110, 144–152 (2002).
Collette, N. M. et al. Targeted deletion of Sost distal enhancer increases bone formation and bone mass. Proc. Natl Acad. Sci. USA 109, 14092–14097 (2012).
Little, R. D. et al. A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. Am. J. Hum. Genet. 70, 11–19 (2002).
Ellies, D. L. et al. Bone density ligand, Sclerostin, directly interacts with LRP5 but not LRP5G171V to modulate Wnt activity. J. Bone Miner. Res. 21, 1738–1749 (2006).
van Wesenbeeck, L. et al. Six novel missense mutations in the LDL receptor-related protein 5 (LRP5) gene in different conditions with an increased bone density. Am. J. Hum. Genet. 72, 763–771 (2003).
Williams, B. O. & Insogna, K. L. Where Wnts went: the exploding field of Lrp5 and Lrp6 signaling in bone. J. Bone Miner. Res. 24, 171–178 (2009).
Bhat, B. M. et al. Structure-based mutation analysis shows the importance of LRP5 β-propeller 1 in modulating Dkk1-mediated inhibition of Wnt signaling. Gene 391, 103–112 (2007).
Semenov, M. V. & He, X. LRP5 mutations linked to high bone mass diseases cause reduced LRP5 binding and inhibition by SOST. J. Biol. Chem. 281, 38276–38284 (2006).
Babij, P. et al. High bone mass in mice expressing a mutant Lrp5 gene. J. Bone Miner. Res. 18, 960–974 (2003).
Balemans, W. & van Hul, W. The genetics of low-density lipoprotein receptor-related protein 5 in bone: a story of extremes. Endocrinology 148, 2622–2629 (2007).
Kato, M. et al. Cbfa1-independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in Lrp5, a Wnt coreceptor. J. Cell Biol. 157, 303–314 (2002).
Holmen, S. L. et al. Decreased BMD and limb deformities in mice carrying mutations in both Lrp5 and Lrp6. J. Bone Miner. Res. 19, 2033–2040 (2004).
Li, C. et al. Disruption of LRP6 in osteoblasts blunts the bone anabolic activity of PTH. J. Bone Miner. Res. http://dx.doi.org/10.1002/jbmr.1962.
Choi, H. Y., Dieckmann, M., Herz, J. & Niemeier, A. Lrp4, a novel receptor for Dickkopf 1 and sclerostin, is expressed by osteoblasts and regulates bone growth and turnover in vivo. PLoS ONE 4, e7930 (2009).
Li, Y. et al. LRP4 mutations alter Wnt/β-catenin signaling and cause limb and kidney malformations in Cenani–Lenz syndrome. Am. J. Hum. Genet. 86, 696–706 (2010).
Rivadeneira, F. et al. Twenty bone-mineral-density loci identified by large-scale meta-analysis of genome-wide association studies. Nat. Genet. 41, 1199–1206 (2009).
Byers, P. H. & Pyott, S. M. Recessively inherited forms of osteogenesis imperfecta. Annu. Rev. Genet. 46, 475–497 (2012).
Fahiminiya, S. et al. Mutations in WNT1 are a cause of osteogenesis imperfecta. J. Med. Genet. 50, 345–348 (2013).
Keupp, K. et al. Mutations in WNT1 cause different forms of bone fragility. Am. J. Hum. Genet. 92, 565–574 (2013).
Laine, C. M. et al. WNT1 mutations in early-onset osteoporosis and osteogenesis imperfecta. N. Engl. J. Med. 368, 1809–1816 (2013).
Pyott, S. M. et al. WNT1 mutations in families affected by moderately severe and progressive recessive osteogenesis imperfecta. Am. J. Hum. Genet. 92, 590–597 (2013).
Canalis, E. Update in new anabolic therapies for osteoporosis. J. Clin. Endocrinol. Metab. 95, 1496–1504 (2010).
Canalis, E. Growth factor control of bone mass. J. Cell. Biochem. 108, 769–777 (2009).
Ominsky, M. S. et al. Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength. J. Bone Min. Res. 25, 948–959 (2010).
Padhi, D., Jang, G., Stouch, B., Fang, L. & Posvar, E. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J. Bone Miner. Res. 26, 19–26 (2011).
McClung, M. R. et al. Inhibition of sclerostin with AMG 785 in postmenopausal women with low bone mineral density: phase 2 trial results [abstract 1025]. J. Bone Miner. Res. 27 (Suppl. 1), (2012).
US National Library of Medicine. ClinicalTrials.gov [online], (2013).
US National Library of Medicine. ClinicalTrials.gov [online], (2013).
Tian, E. et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N. Engl. J. Med. 349, 2483–2494 (2003).
Heath, D. J. et al. Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma. J. Bone Miner. Res. 24, 425–436 (2009).
Fulciniti, M. et al. Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood 114, 371–379 (2009).
Pozzi, S. et al. In vivo and in vitro effects of a novel anti-Dkk1 neutralizing antibody in multiple myeloma. Bone 53, 487–496 (2013).
Wang, F. S., Ko, J. Y., Yeh, D. W., Ke, H. C. & Wu, H. L. Modulation of Dickkopf-1 attenuates glucocorticoid induction of osteoblast apoptosis, adipocytic differentiation, and bone mass loss. Endocrinology 149, 1793–1801 (2008).
Wang, F. S. et al. Secreted frizzled-related protein 1 modulates glucocorticoid attenuation of osteogenic activities and bone mass. Endocrinology 146, 2415–2423 (2005).
Canalis, E., Mazziotti, G., Giustina, A. & Bilezikian, J. P. Glucorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos. Int. 18, 1319–1328 (2007).
Betts, A. M. et al. The application of target information and preclinical pharmacokinetic/pharmacodynamic modeling in predicting clinical doses of a Dickkopf-1 antibody for osteoporosis. J. Pharmacol. Exp. Ther. 333, 2–13 (2010).
Bodine, P. V. et al. A small molecule inhibitor of the Wnt antagonist secreted frizzled-related protein-1 stimulates bone formation. Bone 44, 1063–1068 (2009).
Bienz, M. & Clevers, H. Linking colorectal cancer to Wnt signaling. Cell 103, 311–320 (2000).
Tashjian, A. H. Jr & Goltzman, D. On the interpretation of rat carcinogenicity studies for human PTH1–34 and human PTH1–84 . J. Bone Miner. Res. 23, 803–811 (2008).
Edwards, C. M. et al. Increasing Wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivo. Blood 111, 2833–2842 (2008).
Raz, R. et al. The mutation ROR2W749X, linked to human BDB, is a recessive mutation in the mouse, causing brachydactyly, mediating patterning of joints and modeling recessive Robinow syndrome. Development 135, 1713–1723 (2008).
Yamaguchi, T. P., Bradley, A., McMahon, A. P. & Jones, S. A Wnt5a pathway underlies outgrowth of multiple structures in the vertebrate embryo. Development 126, 1211–1223 (1999).
Tu, X. et al. Noncanonical Wnt signaling through G protein-linked PKCδ activation promotes bone formation. Dev. Cell 12, 113–127 (2007).
Bradley, E. W. & Drissi, M. H. WNT5A regulates chondrocyte differentiation through differential use of the CaN/NFAT and IKK/NF-κB pathways. Mol. Endocrinol. 24, 1581–1593 (2010).
Maeda, K. et al. Wnt5a–Ror2 signaling between osteoblast-lineage cells and osteoclast precursors enhances osteoclastogenesis. Nat. Med. 18, 405–412 (2012).
Topol, L. et al. Wnt-5a inhibits the canonical Wnt pathway by promoting GSK-3-independent β-catenin degradation. J. Cell Biol. 162, 899–908 (2003).
Acknowledgements
The author's research work is supported by funding from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (grant numbers AR021707 and AR063049) and from the National Institute of Diabetes & Digestive & Kidney Diseases (grant number DK045227), both part of the NIH. The content is solely the responsibility of the author and does not necessarily represent the official views of the NIH.
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author declares that he has acted as a consultant for Amgen and Eli Lilly and is a member of the speaker's bureau for Eli Lilly.
Rights and permissions
About this article
Cite this article
Canalis, E. Wnt signalling in osteoporosis: mechanisms and novel therapeutic approaches. Nat Rev Endocrinol 9, 575–583 (2013). https://doi.org/10.1038/nrendo.2013.154
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrendo.2013.154
This article is cited by
-
Investigating the impact of Wnt pathway-related genes on biomarker and diagnostic model development for osteoporosis in postmenopausal females
Scientific Reports (2024)
-
Network regulatory mechanism of ncRNA on the Wnt signaling pathway in osteoporosis
Cell Division (2023)
-
The Sequential Therapy in Osteoporosis
Indian Journal of Orthopaedics (2023)
-
Roxadustat promotes osteoblast differentiation and prevents estrogen deficiency-induced bone loss by stabilizing HIF-1α and activating the Wnt/β-catenin signaling pathway
Journal of Orthopaedic Surgery and Research (2022)
-
miR-215-5p regulates osteoporosis development and osteogenic differentiation by targeting XIAP
BMC Musculoskeletal Disorders (2022)